Eurand Announces Conference Call On Second Quarter 2008 Financial Results

Corporate news announcement processed and transmitted by Hugin ASA.
The issuer is solely responsible for the content of this
announcement.
----------------------------------------------------------------------
--------------

Eurand Announces Conference Call On Second Quarter 2008 Financial
Results
Body:

AMSTERDAM, The Netherlands, July 18, 2008 (PRIME NEWSWIRE) -- Eurand
N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops,
manufactures and commercializes enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug formulation
technologies, will host a conference call on Thursday, August 7, 2008
at 8:30 AM ET to discuss its second quarter 2008 financial results.
The conference call will be hosted by Gearoid Faherty, Chief
Executive Officer, and Mario Crovetto, Chief Financial Officer.

The conference call schedule is as follows:

7:00 a.m. ET: Second quarter 2008 financial results will be released

8:20 a.m. ET: To participate in the conference call:

-- U.S. Participants dial 1-877-407-9039

-- International Participants dial +1-201-689-8470

8:30 a.m. ET: Conference call begins promptly

Call Replay: A replay of the call will be available until September
7, 2008. The Account Number is: 3055, Conference ID Number: 291529.

-- U.S. Participants dial 1-877-660-6853

-- International Participants dial +1-201-612-7415

A live webcast of the call will also be available from the Investor
Relations section of the corporate web site at www.eurand.com.
Following the live webcast, the archived version of the call will be
available at the same URL until September 7, 2008.

About Eurand

Eurand is a specialty pharmaceutical company that develops,
manufactures and commercializes enhanced pharmaceutical and
biopharmaceutical products based on its proprietary drug formulation
technologies. Eurand has had four partnered products approved by the
FDA since 2001 and has a pipeline of product candidates in
development for itself and its collaboration partners. Eurand
completed two phase III clinical trials for EUR-1008 (Zentase),
intended for the treatment of Exocrine Pancreatic Insufficiency and,
as announced on June 18, 2008, received an approvable letter from the
FDA for its NDA for this product. Eurand's technology platforms
include bioavailability enhancement of poorly soluble drugs,
customized release, taste-masking/fast-dissolving formulations and
drug conjugation. Eurand is a global company with facilities in the
USA and Europe. For more information, visit Eurand's website at
www.eurand.com.

CONTACT:
Eurand
Bill Newbould, Vice President, Investor Relations
+1 267-759-9335
bill.newbould@eurand.com

The Ruth Group
Nick Laudico
+1 646-536-7030
nlaudico@theruthgroup.com
Sara Ephraim
+1 646-536-7002
sephraim@theruthgroup.com

--- End of Message ---

Eurand N.V.
845 Center Drive Vandalia, Ohio USA

WKN: A0MSPK; ISIN:
NL0000886448;
;
Copyright © Hugin AS 2008. All rights reserved.